- Home
- XGN vs EPRX Comparison
XGN vs EPRX Comparison
Compare XGN & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- EPRX
- Stock Information
- Founded
- XGN 2002
- EPRX 2011
- Country
- XGN United States
- EPRX Canada
- Employees
- XGN N/A
- EPRX N/A
- Industry
- XGN Medical Specialities
- EPRX
- Sector
- XGN Health Care
- EPRX
- Exchange
- XGN Nasdaq
- EPRX NYSE
- Market Cap
- XGN 138.3M
- EPRX 137.7M
- IPO Year
- XGN 2019
- EPRX N/A
- Fundamental
- Price
- XGN $7.00
- EPRX $5.09
- Analyst Decision
- XGN Strong Buy
- EPRX Strong Buy
- Analyst Count
- XGN 2
- EPRX 1
- Target Price
- XGN $7.50
- EPRX $12.00
- AVG Volume (30 Days)
- XGN 237.8K
- EPRX 12.5K
- Earning Date
- XGN 08-04-2025
- EPRX 08-07-2025
- Dividend Yield
- XGN N/A
- EPRX N/A
- EPS Growth
- XGN N/A
- EPRX N/A
- EPS
- XGN N/A
- EPRX N/A
- Revenue
- XGN $56,724,000.00
- EPRX N/A
- Revenue This Year
- XGN $19.39
- EPRX N/A
- Revenue Next Year
- XGN $13.27
- EPRX N/A
- P/E Ratio
- XGN N/A
- EPRX N/A
- Revenue Growth
- XGN 1.78
- EPRX N/A
- 52 Week Low
- XGN $1.71
- EPRX $2.20
- 52 Week High
- XGN $7.95
- EPRX $5.90
- Technical
- Relative Strength Index (RSI)
- XGN 52.23
- EPRX N/A
- Support Level
- XGN $6.62
- EPRX N/A
- Resistance Level
- XGN $7.35
- EPRX N/A
- Average True Range (ATR)
- XGN 0.48
- EPRX 0.00
- MACD
- XGN -0.10
- EPRX 0.00
- Stochastic Oscillator
- XGN 29.63
- EPRX 0.00
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.